Back to GetFilings.com

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.

_________________

FORM 10-Q
_________________

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.

For the Quarterly Period Ended June 28, 2003

OR

TRANSITIONAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From _________ to ________.

Commission File Number 0-11392

SPAN-AMERICA MEDICAL SYSTEMS, INC.
(Exact name of Registrant as specified in its charter)

70 Commerce Center
Greenville, South Carolina 29615
(Address of Principal Executive Offices) (Zip Code)

        Registrant’s telephone number, including area code: (864) 288-8877

Not Applicable
Former name, former address and former fiscal year, if changed since last report.

Common Stock, No Par Value — 2,550,154 shares as of August 4, 2003

Part 1. FINANCIAL INFORMATION
Item 1. Financial Statements
Span-America Medical Systems, Inc.
Balance Sheets

See accompanying notes.

Note: The Balance Sheet at September 28, 2002 has been derived from the audited financial statements at that date.

Span-America Medical Systems, Inc.
Statements of Income
(Unaudited)

See accompanying notes.

Span-America Medical Systems, Inc.
Statements of Cash Flows
(Unaudited)

See accompanying notes.

SPAN-AMERICA MEDICAL SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
JUNE 28, 2003

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine month period ended June 28, 2003 are not necessarily indicative of the results that may be expected for the year ended September 27, 2003. For further information, refer to the Company's Annual Report on Form 10-K for the year ended September 28, 2002.

NOTE 2 - INVENTORIES

The components of inventories are as follows:

NOTE 3 - PROPERTY AND EQUIPMENT

Property and equipment, at cost, is summarized by major classification as follows:

NOTE 4 - OTHER ASSETS

Other assets consist of the following:

NOTE 5 - EARNINGS PER COMMON SHARE

The following table sets forth the computation of basic and diluted earnings per share in accordance with Statement of Financial Accounting Standards (SFAS) No. 128, "Earnings Per Share."

NOTE 6 - OPERATIONS AND INDUSTRY SEGMENTS

The company reports on three segments of business: medical, custom products, and safety catheters. This industry segment information corresponds to the markets in the United States for which the Company manufactures and distributes its products and therefore complies with the requirements of SFAS No. 131 "Disclosures about Segments of an Enterprise and Related Information."

The following table summarizes certain information on industry segments:

Total sales by industry segment include sales from unaffiliated customers, as reported in the Company's statements of income. In calculating operating profit, non-allocable general corporate expenses, interest expense, other income, and income taxes are not included, but certain corporate operating expenses incurred for the benefit of all segments are included on an allocated basis.

NOTE 7 - SHAREHOLDERS' EQUITY

The Company accounts for stock options under Accounting Principles Board Opinion 25, "Accounting for Stock Issued to Employees." Accordingly, no compensation expense has been charged to operations. Had compensation expense for the plans been determined based on the fair value at the grant dates for awards under the plans consistent with the accounting method available under SFAS No. 123 "Accounting for Stock Based Compensation," the Company's net income and net income per common share would have been reduced to the proforma amounts indicated below:

The fair value of each option grant is estimated on the date of grant using the Black–Scholes option pricing model with the following weighted average assumptions for grants made in 2003 and 2002, respectively: risk–free interest rates of 3.26% and 3.45%; dividend yields of 1.6% and 1.7%; volatility factors of the expected market price of the Company's common stock of .384 and .407; and a weighted average expected life of the option of 8 years for both periods.

NOTE 8 - CONTINGENCIES

From time to time the company is a defendant in legal actions involving claims arising in the normal course of business. The company believes that, as a result of legal defenses and insurance arrangements, none of these actions should have a material adverse effect on its operations or financial condition.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF
INTERIM FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

        Net sales for the third quarter of fiscal 2003 rose 27% to $10.6 million compared with $8.3 million in the third quarter of fiscal 2002. For the year to date in fiscal 2003, net sales increased 29% to $29.3 million from $22.8 million in the same period last year. The increase in net sales for the third quarter and year-to-date resulted mainly from higher unit sales of pillows and Geo-Systems™ mattress pads for the consumer market and higher unit sales of PressureGuard® and Geo-Mattress® therapeutic mattresses for the medical market.

        Net income for the third quarter of fiscal 2003 rose 9% to $392,000, or 15 cents a diluted share, compared with $359,000, or 14 cents a diluted share, in the third quarter of fiscal 2002. The increase in third quarter earnings compared with the prior year resulted from higher sales in the custom products segment, particularly consumer mattress pads, and increased medical mattress sales.

        Net income for the year to date decreased 19% to $951,400 or $0.36 a diluted share, compared with $1.2 million or $0.45 a diluted share, in the first nine months of fiscal 2002. The year-to-date decline was due primarily to higher raw material costs, a less profitable product mix, increased professional fees, and expenses related to the introduction of the new Secure I. V. product line compared with the first nine months of fiscal 2002.

        The Company’s total medical sales increased by 8% to $5.5 million in the third quarter this year from $5.1 million in the same quarter last year. The majority of the growth in medical sales was from our proprietary lines of therapeutic replacement mattresses. Medical mattress sales rose 31% in the third quarter, led by the Company’s newest powered mattresses, The PressureGuard®APM2® and the PressureGuard Easy Air®. Sales of patient positioners increased 4% during the third quarter. Sales of the Company’s Selan® line of skin care products grew by 11% during the quarter as a result of the June introduction of the new Selan Herbal™ barrier cream. Sales of overlays were down by 8%, continuing a long-term trend of customers switching to replacement mattresses from mattress overlays. Seating sales were down 46% in the third quarter compared with the third quarter of fiscal 2002. Last year’s third quarter seating sales included a large one-time sale to a customer in the long term care market. Excluding the special order from last year, seating sales in the third quarter this year would have declined 9% compared with the prior year.

        For the year to date in fiscal 2003, medical sales rose 12% to $15.9 million from $14.2 million in the same period last year. The increase was driven by higher unit volumes of mattresses and positioners, which grew by 37% and 7%, respectively. These increases were partly offset by volume declines in overlays and seating, which decreased by 11% and 26%, respectively. Management expects sales of medical products for the fourth quarter of fiscal 2003 to be similar to those of the first three quarters of this fiscal year.

        Sales in the custom products segment increased by 57% during the third quarter to $5.1 million from $3.3 million in the same period last year. For the year-to-date, custom products sales increased 56% to $13.5 million from $8.6 million in the same period last year. The custom products segment includes consumer and industrial foam products. Sales of consumer foam products increased 68% in the third quarter and 69% for the year to date compared with the same periods last year. The majority of the increase was the result of increased shipments of Geo-tech™ foam mattress pads sold to Wal-Mart through our marketing partner, Louisville Bedding Company. Sales of our industrial product lines have increased with the improving manufacturing economy, resulting in increased orders from new and existing customers. Industrial sales increased 11% in the third quarter of 2003 and 15% for the year-to-date compared with the same periods in 2002. Management expects that custom product sales during the fourth quarter of fiscal 2003 will be similar to or slightly less than those of the same period last year mainly due to the comparison with our excellent sales performance in the fourth quarter of 2002.

        The Company’s gross profit level increased by 15% in the third quarter of fiscal 2003 to $2.91 million from $2.53 million in the third quarter last year. For the year to date in fiscal 2003, gross profit increased 10% to $8.05 million from $7.30 million. The increases in gross profit level for the third quarter and year to date periods were mainly due to higher sales volume and improved manufacturing efficiencies. The gross margin percentage for the third quarter decreased to 27.4% compared with 30.3% in the third quarter last year. The gross margin percentage for the year to date in 2003 decreased to 27.4% compared with 32.0% for the year to date in fiscal 2002. The decline in gross margin percentage for the third quarter and the year to date resulted from raw material cost increases due to higher prices on foam (our largest volume raw material). Span-America has received three price increases on foam raw materials during the past 12 months and has only been partially successful at passing these higher costs along to customers. Higher consumer sales in 2003 compared with 2002 also reduced margins since they carry lower margins than those associated with the Company’s medical business. The medical segment has historically had a higher gross margin than the custom products segment mainly because most of the Company’s medical products are patented and proprietary. Management expects the Company’s gross margin percentage for the remainder of fiscal 2003 to be less than that of fiscal 2002 because of higher foam costs and a less profitable sales mix.

        Sales and marketing expenses increased by $196,000 (13%) to $1.67 million during the third quarter of fiscal 2003 compared with the same quarter last year. For the year to date in fiscal 2003, these expenses increased $545,000 (13%) to $4.77 million compared with $4.23 million for the same period last year. For both the quarter and the year-to-date periods, the increases were mainly in the areas of evaluation samples and commissions. Year to date sales and marketing expenses for 2003 include $69,000 related to the Secure I. V. product line of safety catheters acquired in July 2002 which is further discussed below. Total sales and marketing expenses for the fourth quarter of fiscal 2003 are expected to be similar to those of the third quarter just completed.

        Total research and development expenses were up 80% to $144,000 compared with $80,000 in the third quarter of fiscal 2002 as a result of work on the Secure I.V. product line. Third quarter research and development expenses related to the preparation for launch of the new Secure I.V. product line were $83,000. Total research and development expenses for the year to date in fiscal 2003 were up 93% to $429,000 compared with $222,000 in the first three quarters of fiscal 2002. Research and development expenses for the first three quarters of 2003 included $235,000 for product development and preparation for the introduction of the Secure I.V. product line. We anticipate that initial sales of Secure I.V. products will occur in early fiscal 2004 and will not offset higher marketing and development expenses related to the product line’s introduction during the period.

        General and administrative expenses increased $63,000 (11%) for the third quarter of fiscal 2003 to $645,000 compared with $582,000 in the third fiscal quarter of last year. For the year-to-date in fiscal 2003, general and administrative expenses increased $236,000 (14%) to $1.91 million compared with $1.67 million for the same period in fiscal 2002. The increase in both periods was related primarily to higher professional fees and higher property and casualty insurance costs. Expenses related to various proposals by Mr. Jerry Zucker, which are more fully discussed in Part II, Item 1. Legal Proceedings, were approximately $85,000 in the third quarter. The Company incurred professional fees in the second quarter of approximately $130,000, or $0.03 per share after taxes, related to the amendment and restatement of the Company’s shareholder rights plan, which was due to expire this year. General and administrative expenses for fiscal 2003 are expected to be higher than those of 2002 as a result of anticipated ongoing expenses related to the proposals by Mr. Zucker.

        Non-operating income remained level at $160,000 in the third quarter of fiscal 2003 compared with the same quarter last year. For the fiscal year to date, non-operating income decreased by 17% to $529,000 in fiscal 2003 compared with the same period last year. The decrease was caused by a one-time, pre-tax gain in the second quarter of fiscal 2002 of $84,000 ($55,000 or 2 cents a share after taxes) as a result of common stock received through the demutualization of Prudential Insurance Company. Royalty income on a shielded syringe product licensed to Becton and Dickinson Company (BD) increased 3% to $139,000 during the third quarter of 2003 compared with the third quarter of 2002. For the year to date in fiscal 2003, royalty income decreased 3% to $457,000 compared with the same period last year. The Company’ license agreement with BD is scheduled to expire in December 2005, and the associated royalty income will be eliminated.

        The Company’s investment income declined by 21% in the third quarter of fiscal 2003 and 10% for the year to date. The decline in investment income is the result of lower interest rates on the Company’s marketable debt securities and to a lesser extent to a decline in the level of marketable securities during fiscal 2003. Management expects total non-operating income for the remainder of fiscal 2003 to be slightly less than that of the same period in fiscal 2002.

        During the first nine months of fiscal 2003, the Company paid dividends of $267,000 or 28% of net income for the year-to-date period. This amount represented three quarterly dividends of $0.035 per share.

        The statements contained in “Results of Operations” which are not historical facts are forward-looking statements that involve risks and uncertainties. Management wishes to caution the reader that these forward-looking statements such as the Company’s expectations for future sales and expense levels compared with previous periods are forecasts. Actual events or results may differ materially as a result of risks facing the Company. Such risks include but are not limited to: (a) the loss of a major distributor of the Company’s products, (b) the inability to achieve anticipated sales volumes, (c) raw material cost increases, (d) changes in relationships with large customers, (e) the inability to achieve sales or cost targets for the Secure I.V. product line, (f) potential design and production difficulties for the Secure I.V. product line, (g) the impact of competitive products and pricing, (h) government reimbursement changes in the medical market, (i) FDA regulation of medical device manufacturing, and other risks referenced in the Company’s Annual Report on Form 10-K.

LIQUIDITY AND CAPITAL RESOURCES